Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.04
-9.7%
$2.68
$2.00
$9.19
$20.41M1.114.62 million shs679,869 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.70
+1.1%
$3.46
$2.57
$6.88
$22.61M0.643,281 shs820 shs
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
$2.15
$2.45
$2.00
$13.95
$5.56M0.49268,490 shs10,358 shs
Rallybio Corporation stock logo
RLYB
Rallybio
$0.51
-3.2%
$0.40
$0.22
$1.25
$21.96M-1.12752,089 shs316,118 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-9.73%-15.00%-15.00%-29.90%-36.84%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+1.09%-1.20%+11.45%+14.55%-30.45%
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
0.00%-0.46%-10.79%-2.27%+214,999,900.00%
Rallybio Corporation stock logo
RLYB
Rallybio
-3.16%+9.89%-0.08%+74.40%-57.42%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
1.3341 of 5 stars
3.32.00.00.01.90.00.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
2.3226 of 5 stars
3.55.00.00.00.80.00.6
Rallybio Corporation stock logo
RLYB
Rallybio
1.9688 of 5 stars
3.02.00.00.01.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.50
Moderate Buy$12.00488.24% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
3.00
Buy$33.001,434.88% Upside
Rallybio Corporation stock logo
RLYB
Rallybio
2.00
Hold$10.001,856.95% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$10K1,842.12N/AN/A($0.69) per share-2.96
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.20N/AN/A$13.32 per share0.28
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/AN/AN/AN/A$12.73 per shareN/A
Rallybio Corporation stock logo
RLYB
Rallybio
$848K25.08N/AN/A$1.49 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$0.17N/AN/AN/AN/AN/A-8.14%8/11/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
-$7.24M-$0.42N/AN/AN/AN/A-14.04%-12.39%8/15/2025 (Estimated)
Rallybio Corporation stock logo
RLYB
Rallybio
-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%N/A

Latest PPBT, NAII, RLYB, and DARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025N/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
-$0.21N/AN/AN/AN/AN/A
8/11/2025Q2 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.55N/AN/AN/A$0.14 millionN/A
8/6/2025Q2 2025
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
-$0.21-$0.40-$0.19-$0.40N/AN/A
5/21/2025Q1 2025
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/A-$0.17N/A-$0.17N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million
5/8/2025Q1 2025
Rallybio Corporation stock logo
RLYB
Rallybio
-$0.21-$0.21N/A-$0.21N/A$0.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.56
0.56
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/A
2.72
2.72
Rallybio Corporation stock logo
RLYB
Rallybio
N/A
14.68
14.68

Institutional Ownership

CompanyInstitutional Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
9.64%
Rallybio Corporation stock logo
RLYB
Rallybio
90.34%

Insider Ownership

CompanyInsider Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
2.98%
Rallybio Corporation stock logo
RLYB
Rallybio
8.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
309.03 million8.67 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
202.59 million2.51 millionOptionable
Rallybio Corporation stock logo
RLYB
Rallybio
4041.61 million37.99 millionNot Optionable

Recent News About These Companies

Evercore ISI Remains a Hold on Rallybio (RLYB)
Jones Trading Downgrades Rallybio (RLYB)
Rallybio downgraded to Hold from Buy at JonesResearch
Rallybio downgraded to In Line from Outperform at Evercore ISI
Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright
Rallybio discontinues RLYB212 program
Rallybio sinks as it drops RLYB212 for prevention of FNAIT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.04 -0.22 (-9.73%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.05%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.71 +0.05 (+1.34%)
As of 08/7/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Purple Biotech stock logo

Purple Biotech NASDAQ:PPBT

$2.15 0.00 (0.00%)
Closing price 08/7/2025 03:58 PM Eastern
Extended Trading
$2.16 +0.02 (+0.70%)
As of 08/7/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.51 -0.02 (-3.16%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.51 0.00 (0.00%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.